Genea Biocells Publishes First Human Stem Cell Model of Facioscapulohumeral Muscular Dystrophy (FSHD) – PR Newswire (press release)
|
Genea Biocells Publishes First Human Stem Cell Model of Facioscapulohumeral Muscular Dystrophy (FSHD)
PR Newswire (press release) SAN DIEGO, May 24, 2016 /PRNewswire/ — Californian/Australian drug discovery company Genea Biocells has demonstrated and described the world’s first human stem cell-based cellular model for a muscular dystrophy that is suitable for high-throughput … |
Toledo Blade |
Stem Cell Bone Marrow Breakthrough
Energy and Capital We’ve recently told you about a stem cell advancement could double food production, a key to possibly ending world hunger. Well now we’ve heard of another advance, a medical one, that could help us eradicate some of humanities worst and most painful … Ask before stem–cell therapyToledo Blade Stem cell advance could be key step toward treating deadly blood diseasesBiotechin.Asia Broadening Scope of Stem Cell Research Propels Global Cell Expansion MarketIndustry Today (press release) |
DTN The Progressive Farmer (registration) (blog) |
Stem Cell Discovery Sends Corn Yields Soaring
DTN The Progressive Farmer (registration) (blog) The team of scientists, led by David Jackson, isolated a chemical signal from the leaves of a plant that acts like a brake on stem cell growth to control the plant’s growth and development. In a CSH video, Jackson used an architecture analogy to help … |
Multiple Sclerosis News Today |
Modern Medicine’s Promising Future for MS Treatment: Stem Cell Therapy
Multiple Sclerosis News Today Multiple sclerosis research shows that adipose-derived mesenchymal stem cell therapy may potentially repair the damage and inflammation seen in the nervous system of patients with MS. But, do you know what stem cells are? “So, you’re reading the … |
|
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation’s Phase I Clinical Trial …
PR Newswire (press release) IRVINE, Calif., May 23, 2016 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem … |
|
Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation’s Phase I Clinical Trial …
PR Newswire (press release) IRVINE, Calif., May 23, 2016 /PRNewswire/ — Cryoport, Inc. (NASDAQ: CYRX) (“Company”), the world’s leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem … |